[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356184-105":59,"doc-detail-356184-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","immuno-oncology-in-the-perioperative-setting-the-next-frontier-in-resectable-head-and-neck-cancers-a-systematic-review","Immuno-oncology in the perioperative setting - the next frontier in resectable head and neck cancers - a systematic review","","Perioperative immunotherapy, especially immune checkpoint inhibitors (ICIs), is presented as a promising approach to reduce relapse in resectable head and neck squamous cell carcinoma (HNSCC), where nearly half of patients recur within five years despite standard multimodal care. A PRISMA-compliant review of trials from 2018–2026 evaluates safety, pathological response, EFS/DFS, and overall survival, without meta-analysis due to heterogeneity. Combination regimens show higher major pathological response and improved survival endpoints, with biomarker and sequencing research ongoing.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immuno-oncology-in-the-perioperative-setting-the-next-frontier-in-resectable-head-and-neck-cancers-a-systematic-review/356184/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immuno-oncology-in-the-perioperative-setting-the-next-frontier-in-resectable-head-and-neck-cancers-a-systematic-review/356184.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is perioperative immunotherapy being explored for resectable head and neck cancers?","Question",{"text":113,"@type":114},"Despite standard multimodal therapy, nearly half of patients with resectable HNSCC experience relapse within five years. Perioperative ICIs aim to reduce recurrence by addressing micro-metastatic disease around curative surgery.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the systematic review conducted and what outcomes were assessed?",{"text":118,"@type":114},"The review followed PRISMA guidelines and searched PubMed, Embase, Cochrane Library, and major oncology conference proceedings (2018–2026). Two reviewers screened and extracted data, focusing on safety, pathological response, EFS/DFS, and overall survival.",{"name":120,"@type":111,"acceptedAnswer":121},"What do the included studies suggest about neoadjuvant and combination strategies?",{"text":122,"@type":114},"Neoadjuvant ICI monotherapy appeared safe but produced modest major pathological response rates (~6%). Combination approaches were more effective, such as IMCISION reporting higher MPR with nivolumab plus ipilimumab versus nivolumab alone.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356184,1790869137,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Kapoor et al. BMC Cancer (2026) 26:1081 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16304-8](https://doi.org/10.1186/s12885-026-16304-8)  \nSYSTEMATIC REVIEW Open Access  \nImmuno-oncology in the perioperative setting: the next frontier in resectable head and neck cancers – a systematic review  \nAkhil Kapoor1*, Anuj Gupta1, Bipinesh Sansar1, Bal Krishna Mishra1, Nandini Menon2, Minit Shah2, Vanita Noronha2 and Kumar Prabhash2  \nAbstract  \nPerioperative immunotherapy—particularly immune checkpoint inhibitors (ICIs)—has emerged as a promising strategy to reduce recurrence in resectable head and neck squamous cell carcinoma (HNSCC) . Despite standard multimodal therapy, nearly half of patients experience relapse within five years. ICIs such as nivolumab and pembrolizumab have transformed recurrent/metastatic HNSCC, and their integration into curative settings is under active investigation.  \nWe conducted a PRISMA-compliant systematic review of PubMed, Embase, Cochrane Library, and major oncology conference proceedings (2018–2026) to identify clinical trials evaluating ICIs in the perioperative setting of HNSCC. Two reviewers independently screened and extracted data. Outcomes of interest included safety, pathological response, event-free or disease-free survival (EFS/DFS), and overall survival (OS) . Meta-analysis was not performed due to heterogeneous study designs.  \nTwenty-five studies (18 published, 7 conference abstracts) met inclusion criteria. Neoadjuvant ICI monotherapy was safe but showed modest major pathological response (MPR) rates (~ 6%) . Combination strategies were more effective: the IMCISION trial reported 35% MPR with nivolumab plus ipilimumab vs. 17% with nivolumab alone. Neoadjuvant therapy did not delay surgery. In the adjuvant setting, the NIVOPOSTOP trial showed improved 3-year DFS with nivolumab plus postoperative chemoradiotherapy (63 . 1% vs. 52. 5%) . The KEYNOTE-689 trial showed perioperative pembrolizumab significantly improved EFS (51 .8 vs. 30.4 months), leading to FDA approval in PD-L1 CPS ≥ 1 tumors.  \nPathologic response correlated with improved survival. Ongoing trials are refining biomarkers, combinations, and sequencing. Perioperative immunotherapy is reshaping curative-intent management of HNSCC, establishing a new multidisciplinary treatment paradigm.  \nKeywords Head and neck squamous cell carcinoma, Perioperative immunotherapy, Checkpoint inhibitors, Neoadjuvant therapy, Nivolumab and pembrolizumab  \n*Correspondence:  \nAkhil Kapoor  \n[kapoorakhil1987@gmail.com](kapoorakhil1987@gmail.com)  \n1Department of Medical Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi 221005, India 2Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.]","cbCaiji4A1V8RTko","https://ap.wps.com/l/cbCaiji4A1V8RTko","pdf",1793274,"English","# Abstract\n# Introduction\n# Immuno-oncology in perioperative management\n## Clinical trials and outcomes\n## Ongoing directions","[{\"question\":\"Why is perioperative immunotherapy being explored for resectable head and neck cancers?\",\"answer\":\"Despite standard multimodal therapy, nearly half of patients with resectable HNSCC experience relapse within five years. Perioperative ICIs aim to reduce recurrence by addressing micro-metastatic disease around curative surgery.\"},{\"question\":\"How was the systematic review conducted and what outcomes were assessed?\",\"answer\":\"The review followed PRISMA guidelines and searched PubMed, Embase, Cochrane Library, and major oncology conference proceedings (2018–2026). Two reviewers screened and extracted data, focusing on safety, pathological response, EFS/DFS, and overall survival.\"},{\"question\":\"What do the included studies suggest about neoadjuvant and combination strategies?\",\"answer\":\"Neoadjuvant ICI monotherapy appeared safe but produced modest major pathological response rates (~6%). Combination approaches were more effective, such as IMCISION reporting higher MPR with nivolumab plus ipilimumab versus nivolumab alone.\"}]","Immuno-oncology in the perioperative setting - the next frontier in resectable head and neck cancers - a systematic review | PDF",1790123892,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45446d0add90db42bdc260632fd04c85.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2671cd1307d8f81e6ea293690ae14f9.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2564c9e594fd1fdee17401396edabda2.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d0e87f1ff0a8881c8709cbc41053880.webp",980,1306]